knowledge -WSS

knowledge

author：hotspot 2025-09-30 00:01:03 - browse：21975

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： My daughter's legacy lives on through her writing, phage therapy

hotspot

focus

WSS

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Health care court cases: Humana, Sutter, Novant

Finland to offer bird flu vaccine to select groups of people, a possible global first

5 takeaways from STAT's examination of Zynex Medical

Statins may not be needed by millions of people, study suggests

Finland to offer bird flu vaccine to select groups of people, a possible global first

hotspot

knowledge

hotspot

How to save PrEP access — and even expand it

Stopping antidepressants leads to symptoms for 1 in 6 patients

Jerome Adams on the need for new antivirals for Covid

CMS got Medicare Advantage quality rating wrong, judge rules

In Memoriam: Notable people who died in 2023

Structure Therapeutics oral GLP

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ASCO Daily Recap: CAR

Affirmative action in medical school literally saved lives

CMS got Medicare Advantage quality rating wrong, judge rules

entertainment

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Data don't support strong claims for Covid

Pharma companies must ensure equitable access to obesity drugs

5 takeaways from STAT's examination of Zynex Medical

Statins may not be needed by millions of people, study suggests

explore

hotspot

focus

knowledge